TickerTalks
Browse all tickers →
TickerTalks›$DNTH
DNDNTH

Dianthus Therapeutics, Inc.

$DNTH·$4.6B·Biotechnology·Healthcare
$74.53-0.3%YTD+81.3%1Y+105.9%
Price updated 11h ago·X counts updated 4d ago
DNDNTH
$DNTHDianthus Therapeutics, Inc.
$74.53-0.31%30 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $DNTH on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

30X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $DNTH's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $DNTH — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Dianthus Therapeutics up 115% YTD on claseprubart momentum — the AANEM data presentations are the next catalyst.

Dianthus Therapeutics is a clinical-stage biopharma whose lead asset claseprubart targets complement-driven autoimmune diseases. The 2026 breakout reflects specific pipeline progress meeting conference catalyst setup.

  • The P&L is pre-revenue: Q2 revenue was $463K (down 60.2% YoY from a tiny base) at a -10,050% operating margin and EPS of -$0.85, with trailing EPS prints missing Street estimates by 6.3% and beating by 27.4% — these are the small-dollar expense-accrual-driven swings typical of a clinical-stage biotech.
  • The specific catalyst stack is substantive: claseprubart data presentations planned for 2026 AANEM Annual Meeting, Citi's Biopharma Back to School Summit presentation, and continued inducement-grant activity — three coordinated conference-and-grant signals.

At 65% of its 52-week range going into Nov 5 earnings and the AANEM meeting, the setup is coiled on specific clinical-data presentation events. A positive claseprubart AANEM data readout plus any specific regulatory-pathway commentary is the trigger for continuation; a safety-signal or dilution surprise is the invalidation.

What to watch: Nov 5 Q3 earnings and the 2026 AANEM Annual Meeting — claseprubart data outcome, cash runway, regulatory-pathway commentary, and pipeline-progression updates. Positive AANEM data plus clean cash is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-05 — Q3 earnings

event ahead 30dclinical catalyst

Read the AI verdict on $DNTH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage autoimmune biotech targeting complement pathways; lead candidate claseprubart is in trials for rare severe autoimmune diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DNTH.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $DNTH

Neutral — Clinical-stage autoimmune biotech targeting complement pathways; lead candidate claseprubart is in trials for rare severe autoimmune diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-920.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-15.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-143%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3165.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-1.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
94.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.90$-0.85-6.3%
Q1 2026May 5, 2026$-0.85$-1.17+27.4%
Q4 2025Mar 9, 2026$-1.43$-0.98-45.9%
Q3 2025Nov 5, 2025$-0.97$-0.86-12.8%
Next earningsThu, Nov 5·consensus EPS $-0.94

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$463K-60.2%83.6%-10050%$-0.85$-28.9M
Q4 FY25$284K-78.6%100%-24486%$2.59$-47.1M
Q3 FY25$396K-81.8%100%-10174%$-0.97$-30.6M
Q2 FY25$193K-89.6%100%-18097%$-0.88$-23.9M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.9M$1.1M – $2.5M-$3.79-$4.08 – -$3.6411
FY27$2.0M$1.2M – $3.2M-$4.57-$5.57 – -$3.9310
FY28$14.7M$8.1M – $23.2M-$5.62-$7.81 – -$3.0713
FY29$245.4M$135.5M – $385.7M-$3.28-$5.71 – -$1.3711
FY30$778.7M$430.0M – $1.2B$2.87$1.20 – $5.016

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.49%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-25.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-10.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 46.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.085-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 17Edward CarrCHIEF ACCOUNTING OFFICER20.0K sh$2.0MSellSep 1Simrat RandhawaEVP, Head of R&D23.1K sh$2.5MSellAug 19Simon ReadDirector2.8K sh$327KSellAug 10Adam M VenessSVP, General Counsel and Sec.16.2K sh$1.8MSellAug 10Anne McgeorgeDirector7.8K sh$845KSellAug 10Simon ReadDirector2.8K sh$304KSellAug 7Adam M VenessSVP, General Counsel and Sec.3.8K sh$424KSellAug 7Marino GarciaCEO36.7K sh$4.0MSellJul 9Ryan SavitzCFO31.2K sh$3.2MSellJun 17Adam M VenessSVP, General Counsel and Sec.30.0K sh$2.4M
1–10 of 12
+ 20 other (13 exempts · 7 awards) in window

See when $DNTH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3ASRAuto-shelf registrationSep 18S-3ASR
8-KShareholder voteMay 228-K — Item 5.07: Shareholder vote
AI summary

Dianthus Therapeutics (DNTH) — 8-K (Item 5.07) reporting shareholder vote results from the annual meeting held May 21, 2026. Covers the election of directors and other routine annual-meeting proposals. Administrative — routine shareholder vote disclosure; refer to the full filing for vote tallies and whether any proposals failed.

+ 16 other (11 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaglobenewswire.com·3d agoDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·15d agoDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meetingglobenewswire.com·17d agoDianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com·37d agoDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·44d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $DNTH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport